The AMP Studies showed that the VRC01 broadly neutralizing monoclonal antibody can safely prevent the acquisition of some types of HIV.

  • However, the AMP VRC01 infusions did not provide statistically significant prevention of HIV acquisition overall.
  • This means that we will probably need to use more than one antibody to achieve effective antibody mediated HIV prevention.

The AMP Studies were fully enrolled in October 2018. The pair of Phase 2b clinical trials run by the HIV Vaccine Trials Network (HVTN) and the HIV Prevention Trials Network (HPTN) enrolled 4,625 participants at risk for HIV infection from communities in North and South America, Europe, and sub-Saharan Africa.

The studies are ongoing and remain blinded until all participants have completed their final study visits, which are anticipated in early 2021.

More information about the AMP Studies and the results can be found here: